https://doi.org/10.4081/hmr.v1i5.644

New strategies with 90Y-ibritumomab tiuxetan in diffuse large B-cell lymphoma and mantle cell lymphoma

Vol. 1 No. 5: Changing the paradigm: new perspectives in the treatment of haematological malignancies
Published: June 17, 2009
Abstract Views: 168
PDF: 319
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Franck Morschhauser
support@pagepress.org
Both diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) remain major therapeutic challenges in spite of the recent improvements conferred by the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy. Radioimmunotherapy (RIT) which enhances the efficacy of anti-CD20 immunotherapy by taking advantage of the high radiosensitivity of lymphoma cells is an option to improve outcome. Encouraging results with 90Y-ibritumomab tiuxetan as a single agent have been reported in relapsed/refractory DLBCL and MCL. However, in light of the constantly increasing clinical experience with RIT, clinicians face the challenge of how to best integrate this promising new treatment option into existing established treatment algorithms. Preliminary results with 90Y-ibritumomab tiuxetan as a consolidation treatment following first-line immunochemotherapy are promising. By incorporating the most recent data in this rapidly developing field, this review article serves to define the potential role of 90Y-ibritumomab tiuxetan in the overall management of DLBCL and MCL patients not eligible for transplantation.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Morschhauser, F. (2009). New strategies with 90Y-ibritumomab tiuxetan in diffuse large B-cell lymphoma and mantle cell lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 1(5). https://doi.org/10.4081/hmr.v1i5.644
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).